Terms: = Lung cancer AND AKAP9, AKAP350, 10142, ENSG00000127914, KIAA0803, Q99996, AKAP450, YOTIAO, PRKA9, HYPERION, MU-RMS-40_16A, CG-NAP
36 results:
1. Identification and prognostic biomarkers among ZDHHC4/12/18/24, and APT2 in lung adenocarcinoma.
Bian J; Xiong W; Yang Z; Li M; Song D; Zhang Y; Liu C
Sci Rep; 2024 Jan; 14(1):522. PubMed ID: 38177255
[TBL] [Abstract] [Full Text] [Related]
2. Regulation of Chloride Channels by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced α-Defensin 5.
Uemura I; Takahashi-Suzuki N; Kita F; Kobayashi M; Yamada T; Iseki K; Satoh T
Biol Pharm Bull; 2024; 47(1):159-165. PubMed ID: 38171775
[TBL] [Abstract] [Full Text] [Related]
3. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract] [Full Text] [Related]
4. Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in lung cancer through ROS/ER Stress and Mitochondrial Dysfunction.
Liu Z; Wang M; Huang R; Hu T; Jing Y; Huang X; Hu W; Cao G; Wang H
J Med Chem; 2023 Apr; 66(7):4868-4887. PubMed ID: 36946996
[TBL] [Abstract] [Full Text] [Related]
5. TITAN: An end-to-end data analysis environment for the hyperion™ imaging system.
Thirumal S; Jamzad A; Cotechini T; Hindmarch CT; Graham CH; Siemens DR; Mousavi P
Cytometry A; 2022 May; 101(5):423-433. PubMed ID: 35060322
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
7. Activation of TMEM16A Ca
Luo S; Wang H; Bai L; Chen Y; Chen S; Gao K; Wang H; Wu S; Song H; Ma K; Liu M; Yao F; Fang Y; Xiao Q
J Adv Res; 2021 Nov; 33():253-264. PubMed ID: 34603794
[TBL] [Abstract] [Full Text] [Related]
8. Cepharanthine, a novel selective ANO1 inhibitor with potential for lung adenocarcinoma therapy.
Zhang X; Zhang G; Zhao Z; Xiu R; Jia J; Chen P; Liu Y; Wang Y; Yi J
Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119132. PubMed ID: 34450215
[TBL] [Abstract] [Full Text] [Related]
9. Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.
Al-Sanea MM; Al-Ansary GH; Elsayed ZM; Maklad RM; Elkaeed EB; Abdelgawad MA; Bukhari SNA; Abdel-Aziz MM; Suliman H; Eldehna WM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):987-999. PubMed ID: 33985397
[TBL] [Abstract] [Full Text] [Related]
10. Design, Synthesis and Biological Evaluation of Cyanopyridines, Pyridopyrazolopyrimidines and Pyridopyrazolotriazines as Potential Anticancer Agents.
Keshk RM; Izzularab BM
Curr Org Synth; 2021; 18(5):483-492. PubMed ID: 33372879
[TBL] [Abstract] [Full Text] [Related]
11. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract] [Full Text] [Related]
12. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
[TBL] [Abstract] [Full Text] [Related]
13. An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications.
Dasgupta A; Chen KH; Wu D; Hoskin V; Mewburn J; Lima PDA; Parlow LRG; Hindmarch CCT; Martin A; Sykes EA; Tayade C; Lightbody ED; Madarnas Y; SenGupta SK; Elliott BE; Nicol CJB; Archer SL
FASEB J; 2020 Apr; 34(4):5106-5127. PubMed ID: 32068312
[TBL] [Abstract] [Full Text] [Related]
14. Identification of a CIP4 PKA phosphorylation site involved in the regulation of cancer cell invasiveness and metastasis.
Tonucci FM; Almada E; Borini-Etichetti C; Pariani A; Hidalgo F; Rico MJ; Girardini J; Favre C; Goldenring JR; Menacho-Marquez M; Larocca MC
Cancer Lett; 2019 Oct; 461():65-77. PubMed ID: 31319138
[TBL] [Abstract] [Full Text] [Related]
15. TMEM16A as a Potential Biomarker in the Diagnosis and Prognosis of lung cancer.
Hu C; Zhang R; Jiang D
Arch Iran Med; 2019 Jan; 22(1):32-38. PubMed ID: 30821158
[TBL] [Abstract] [Full Text] [Related]
16. Energy layer optimization strategies for intensity-modulated proton therapy of lung cancer patients.
Jensen MF; Hoffmann L; Petersen JBB; Møller DS; Alber M
Med Phys; 2018 Oct; 45(10):4355-4363. PubMed ID: 30129041
[TBL] [Abstract] [Full Text] [Related]
17. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis of novel benzylidene analogues of betulinic acid as potent cytotoxic agents.
Gupta N; Rath SK; Singh J; Qayum A; Singh S; Sangwan PL
Eur J Med Chem; 2017 Jul; 135():517-530. PubMed ID: 28500966
[TBL] [Abstract] [Full Text] [Related]
19. MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression.
Cao Q; Liu F; Ji K; Liu N; He Y; Zhang W; Wang L
J Exp Clin Cancer Res; 2017 Feb; 36(1):29. PubMed ID: 28193228
[TBL] [Abstract] [Full Text] [Related]
20. New Approaches for the Synthesis, Cytotoxicity and Toxicity of Heterocyclic Compounds Derived from 2-Cyanomethylbenzo[c]imidazole.
Mohareb RM; Mohamed AA; Abdallah AE
Acta Chim Slov; 2016; 63(2):227-40. PubMed ID: 27333544
[TBL] [Abstract] [Full Text] [Related]
[Next]
